# The involvement of Th17 inflammation and miR-363-3p in airway epithelial barrier dysfunction

## TL;DR

This study shows that Th17 inflammation and miR-363-3p contribute to airway epithelial barrier dysfunction in asthma, offering potential new biomarkers and treatments.

## Contribution

The study identifies miR-363-3p as a novel microRNA involved in Th17-driven airway epithelial barrier disruption.

## Key findings

- IL-17A and TNFα strongly disrupt airway epithelial barrier integrity compared to other cytokine combinations.
- miR-363-3p targets and suppresses key barrier genes like CLDN8, PCDH1, and PTEN in epithelial cells.
- miR-363-3p levels are elevated in asthma patients and correlate with airway inflammation markers.

## Abstract

Impaired airway epithelial barrier function is a pathogenic driver in a subset of individuals with asthma. MicroRNAs, small RNAs that function as post-transcriptional regulators of gene expression, may be involved in the regulation of the airway epithelial barrier. This study aimed to determine if microRNAs cause epithelial barrier dysfunction through the targeting of mRNAs involved in maintaining airway epithelial barrier integrity.

Primary human bronchial epithelial cells cultured at air–liquid interface were stimulated with cytokines reflecting different asthma endotypes. Barrier integrity was assessed by FITC-labelled dextran flux. Differentially expressed epithelial barrier-related genes and microRNAs were identified by next-generation RNA sequencing and qPCR. Results were validated with microRNA pull-down, treatment with microRNA mimics and antagomirs, respectively, and evaluated in airway samples from subjects with asthma.

A combination of IL-17A and TNFα, mimicking Th17 inflammation, was identified as a strong driver of epithelial barrier disruption, as compared to IL-4 + IL-13, IL-6 + sIL-6R, and TGFβ. Several microRNAs induced by IL-17A and TNFα stimulation were predicted to target barrier-related genes, which exhibited decreased expression in the same model. Of these microRNAs, miR-146a-3p and miR-363-3p were consistently induced in multiple donors. MicroRNA pull-down, overexpression, and knockdown experiments indicated a potential role for miR-363-3p interacting with several barrier-related genes, including CLDN8, PCDH1, and PTEN. Bronchial lavage samples demonstrated an increase of miR-363-3p in individuals with asthma compared to healthy controls, as well as a positive correlation between miR-363-3p and the number of airway eosinophils and neutrophils.

Our results support the role of microRNAs as mediators of cytokine-induced airway epithelial barrier dysfunction. Specifically, miR-363-3p appears to contribute to epithelial damage by targeting and suppressing gene expressions of several key barrier components, including CLDN8, PCDH1, and PTEN, suggesting a novel role for this microRNA in Th17-driven airway disease. A better understanding of microRNA networks and their role in asthma pathogenesis may lead to novel biomarkers and therapeutic targets, which are currently needed for individuals with T2-low asthma and in Th17-driven asthma.

The online version contains supplementary material available at 10.1186/s12931-025-03492-3.